12 completed, 6 unknown, 2 recruiting, 1 terminated. 9 Phase 3, 8 Phase 2, 2 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Unknown 5, Completed 3, Recruiting 1 |
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow Bezafibrate: new trials by email Literature Review of Bezafibrate trials Research Report on Bezafibrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 2382 | 2025-04-15 | 2025-08-03 | |
| Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy Bezafibrate 400 mg in addition to UDCA therapy, Bezafibrate 200 mg in addition to UDCA therapy, Placebo in addition to UDCA therapy - BPC, Non Optimal Response to UDCA | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 108 | 2025-03-27 | 2025-08-27 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg - Primary Biliary Cholangitis | Phase 2 | Completed | Intercept Pharmaceuticals | 72 | 2022-03-21 | 2026-07-16 |
| Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol - Myelodysplastic Syndromes (MDS) | Phase 2 | Unknown | Prof. Janet Dunn | 120 | 2021-12-21 | 2023-10-03 |
| Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy, Placebo of Bezafibrate in addition to standard UDCA therapy - Primary Sclerosing Cholangitis, Cholestasis | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 104 | 2021-04-06 | 2022-05-10 |
| A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis Bezafibrate 200 MG Oral Tablet, Placebo, Ursodeoxycholic Acid - Primary Biliary Cirrhosis | Phase 3 | Unknown | Instituto Mexicano del Seguro Social | 11 | 2020-10-02 | 2021-02-12 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
| Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy Béfizal - Safety Issues, Efficacy, Self | Phase 2 / Phase 3 | Completed | Hôpital Necker-Enfants Malades | 14 | 2019-03-26 | 2023-09-22 |
| BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Bezafibrate - Bipolar Disorder, Depressive Episode | Phase 2 | Completed | Massachusetts General Hospital | 7 | 2018-01-11 | 2026-07-24 |
| Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Alirocumab SAR236553, Atorvastatin, Rosuvastatin - Hypercholesterolemia, Acute Coronary Syndrome | Phase 4 | Completed | Sanofi | 206 | 2016-11-15 | 2019-09-09 |
| Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Bezafibrate, Ursodeoxycholic Acid, Placebo (for Bezafibrate) - Primary Biliary Cirrhosis | Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 34 | 2016-10-01 | 2018-04-23 |
| The Effect of Bezafibrate on Cholestatic Itch Bezafibrate, Placebo - Primary Biliary Cholangitis, Primary Sclerosing Cholangitis | Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 84 | 2016-02-01 | 2016-03-08 |
| A Study of Bezafibrate in Mitochondrial Myopathy Bezafibrate - Mitochondrial Diseases | Phase 2 | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | 6 | 2015-09-01 | 2017-09-21 |
| PC-300 Tea Effect on Triglyceride Levels PC-300 tea., Bezafibrate - Hypertriglyceridemia | Not applicable | Completed | Ciprés Grupo Médico CGM SC | 34 | 2014-01-01 | 2018-08-28 |
| Bezafibrate Plus Berberine in Mixed Dyslipidemia Berberine, Bezafibrate, Berberine plus Bezafibrate - Mixed Dyslipidemia | Phase 3 | Completed | University of Guadalajara | 36 | 2013-04-01 | 2023-02-24 |
| Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Bezafibrate, placebo - PBC | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 100 | 2012-10-15 | 2023-02-27 |
| Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction Bezafibrate - Acute Myocardial Infarction | Phase 4 | Completed | Instituto Mexicano del Seguro Social | 100 | 2011-01-01 | 2014-11-14 |
| The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) Bezafibrate - X-linked Adrenoleukodystrophy, Adrenomyeloneuropathy | Not applicable | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 10 | 2010-07-01 | 2011-08-10 |
| Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Bezafibrate, Placebo - Carnitine Palmitoyltransferase II Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 12 | 2009-10-01 | 2012-05-30 |
| Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes bezafibrate + diflunisal, bezafibrate + placebo - Type 2 Diabetes | Phase 2 | Completed | Zalicus | 150 | 2007-07-01 | 2009-05-13 |
Showing 20 of 21. Sign in to see all of them.
Liver Cirrhosis, Biliary (5) · Carnitine palmitoyl transferase 2 deficiency (2) · Cholangitis, Sclerosing (2) · Cholestasis (2) · Fibrosis (2) · Acute Coronary Syndrome (1) · Adrenoleukodystrophy (1) · Atherosclerosis (1) · Bipolar Disorder (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Digestive System Diseases (1) · Hypercholesterolemia (1) · Hypertriglyceridemia (1)
Assistance Publique - Hôpitaux de Paris (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Instituto Mexicano del Seguro Social (2) · Intercept Pharmaceuticals (2) · Ciprés Grupo Médico CGM SC (1) · Copenhagen University Hospital, Rigshospitalet (1) · Hôpital Necker-Enfants Malades (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Massachusetts General Hospital (1) · Newcastle-upon-Tyne Hospitals NHS Trust (1) · Novartis Pharmaceuticals (1) · Prof. Janet Dunn (1) · Sanofi (1) · University of Guadalajara (1) · Zalicus (1)
France (6) · Mexico (3) · Netherlands (3) · United Kingdom (3) · Canada (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · Germany (1)
Andrew A. Nierenberg, M.D. (1) · Christophe Corpechot, Doctor (1) · Christophe Corpechot, MD (1) · Dominique Bremond Gignac, MD PhD (1) · Edgardo Eric Lopez Mendez, MD (1) · Lynda Szczech (1) · Lynda Szczech, M.D. (1) · Maria A Madrid-Miller, MD (1)
PMID 10051462, PMID 10343514, PMID 10347106, PMID 12360466, PMID 15017671, PMID 15128074, PMID 15468571, PMID 16299032, PMID 16530513, PMID 16848809, PMID 16863557, PMID 17399846, PMID 18752324, PMID 19554543, PMID 22245904, PMID 22259000, PMID 22271046, PMID 22911624, PMID 22911730, PMID 23141888, PMID 24625898, PMID 24671010, PMID 2803071, PMID 28535810, PMID 29606415, PMID 30589964, PMID 31434809, PMID 33031833, PMID 9934730